Homburger advises PHOENIX Pharma on its JV with Voigt Group

The Voigt Group and PHOENIX Pharma Switzerland have decided to bring their subsidiaries Voigt and Voigt Industrie Service and Amedis-UE respectively into a 50/50 joint venture. After receiving clearance from the Swiss Competition Commission, this closing marks the start of the joint future of Amedis-UE, Voigt Pharma Grosshandel and Voigt Industrie Service under the umbrella of avosano. The avosano Group will be an optimally positioned Swiss player in the pharmaceutical wholesale and prewholesale with an expected total turnover of approx. CHF 1.7 billion.

Homburger has advised PHOENIX Pharma Switzerland on the transaction. The team was led by partner Frank Gerhard (corporate/m&a, pictured) and comprises Andreas Burger (regulatory / competition) as well as Patrick Schmidt (corporate/m&a), Allegra Arnold, Daniel Lütolf (both regulatory/competition), Angela Casey (employment), and Fabio Gasser (corporate/m&a).